Boston Trust Walden Corp Increases Holdings in Haemonetics Co. (NYSE:HAE)

Boston Trust Walden Corp lifted its position in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 13.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 809,608 shares of the medical instruments supplier's stock after buying an additional 98,019 shares during the quarter. Boston Trust Walden Corp owned approximately 1.59% of Haemonetics worth $65,076,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Quarry LP bought a new stake in Haemonetics during the second quarter valued at about $39,000. Covestor Ltd boosted its position in Haemonetics by 184.8% during the first quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier's stock valued at $58,000 after purchasing an additional 438 shares in the last quarter. Daiwa Securities Group Inc. bought a new stake in Haemonetics during the second quarter valued at about $82,000. Canada Pension Plan Investment Board purchased a new stake in Haemonetics in the second quarter valued at about $83,000. Finally, EntryPoint Capital LLC purchased a new stake in Haemonetics in the first quarter valued at about $86,000. Institutional investors own 99.67% of the company's stock.

Haemonetics Stock Performance

Haemonetics stock traded down $0.25 during midday trading on Friday, hitting $75.56. 544,455 shares of the company were exchanged, compared to its average volume of 515,492. The firm has a market capitalization of $3.87 billion, a PE ratio of 33.88, a price-to-earnings-growth ratio of 1.16 and a beta of 0.30. Haemonetics Co. has a fifty-two week low of $70.74 and a fifty-two week high of $97.97. The business has a fifty day simple moving average of $75.71 and a two-hundred day simple moving average of $83.23. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.33 and a current ratio of 3.76.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing the consensus estimate of $1.03 by ($0.01). The business had revenue of $336.17 million during the quarter, compared to analyst estimates of $335.08 million. Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The firm's revenue for the quarter was up 8.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.05 earnings per share. On average, sell-side analysts forecast that Haemonetics Co. will post 4.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Barrington Research reiterated an "outperform" rating and issued a $108.00 price target on shares of Haemonetics in a research note on Monday, September 23rd. CL King started coverage on Haemonetics in a research note on Friday, September 13th. They issued a "buy" rating and a $116.00 price objective for the company. BTIG Research started coverage on Haemonetics in a research note on Tuesday, September 10th. They issued a "buy" rating and a $112.00 price objective for the company. Bank of America started coverage on Haemonetics in a research note on Wednesday, September 11th. They issued a "neutral" rating and a $85.00 price objective for the company. Finally, JMP Securities restated a "market outperform" rating and issued a $125.00 price objective on shares of Haemonetics in a research note on Tuesday, August 13th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $106.14.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.